Resource Summary Report

Generated by dkNET on Sep 5, 2026

pcDNA3.1-SARS2-Spike

RRID:Addgene_145032
Type: Plasmid

Proper Citation

RRID:Addgene_145032

Plasmid Information

URL: http://www.addgene.org/145032

Proper Citation: RRID:Addgene_145032

Insert Name: SARS-CoV-2 Spike

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: PMID:32225175

Vector Backbone Description: Backbone Size:5500; Vector Backbone:pcDNA3.1; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Comments: See further use in: Cell entry mechanisms of SARS-CoV-2. Jian Shang, Yushun Wan, Chuming Luo, Gang Ye, Qibin Geng, Ashley Auerbach, and Fang Li. PNAS May 26, 2020 117 (21) 11727-11734 DOI: 10.1073/pnas.2003138117

Plasmid Name: pcDNA3.1-SARS2-Spike

Record Creation Time: 20220422T221818+0000

Record Last Update: 20260905T074906+0000

Ratings and Alerts

No rating or validation information has been found for pcDNA3.1-SARS2-Spike.

No alerts have been found for pcDNA3.1-SARS2-Spike.

Data and Source Information

Source: Addgene

Usage and Citation Metrics

We found 71 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Ito T, et al. (2025) Engineered ACE2 decoy in dry powder form for inhalation: A novel therapy for SARS-CoV-2 variants. Molecular therapy. Methods & clinical development, 33(2), 101459.

Wang S, et al. (2025) Characterization of private mutations in the spike protein of SARS-CoV-2 correlates with viral prevalence. BMC infectious diseases, 25(1), 996.

Kumara D, et al. (2025) Inhibitory Effects of Citrus-Derived Flavonoids Hesperidin and Hesperetin on SARS-CoV-2 Spike-Mediated Syncytia Formation Using In Vitro Cell Model. Advanced pharmaceutical bulletin, 15(2), 416.

Nurisyah S, et al. (2025) Evaluation of an E. coli-expressed spike protein-based in-house ELISA system for assessment of antibody responses after COVID-19 infection and vaccination. Narra J, 5(1), e1250.

Gomez-Zepeda D, et al. (2024) Thunder-DDA-PASEF enables high-coverage immunopeptidomics and is boosted by MS2Rescore with MS2PIP timsTOF fragmentation prediction model. Nature communications, 15(1), 2288.

Lidenge SJ, et al. (2024) Viral Epitope Scanning Reveals Correlation between Seasonal HCoVs and SARS-CoV-2 Antibody Responses among Cancer and Non-Cancer Patients. Viruses, 16(3).

Ye L, et al. (2024) Modulation of alveolar macrophage and mitochondrial fitness by medicinal plant-derived nanovesicles to mitigate acute lung injury and viral pneumonia. Journal of nanobiotechnology, 22(1), 190.

Zhang S, et al. (2024) Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure. Oncotarget, 15, 275.

Cui L, et al. (2024) Enhancing Immune Responses against SARS-CoV-2 Variants in Aged Mice with INDUK: A Chimeric DNA Vaccine Encoding the Spike S1-TM Subunits. ACS omega, 9(32), 34624.

Colom MS, et al. (2024) Complete combinatorial mutational enumeration of a protein functional site enables sequence-landscape mapping and identifies highly-mutated variants that retain activity. Protein science : a publication of the Protein Society, 33(8), e5109.

Khan S, et al. (2024) High-throughput screening identifies broad-spectrum Coronavirus entry inhibitors. iScience, 27(6), 110019.

Lin CH, et al. (2024) Inhibitory Efficacy of Main Components of Scutellaria baicalensis on the Interaction between Spike Protein of SARS-CoV-2 and Human Angiotensin-Converting Enzyme II. International journal of molecular sciences, 25(5).

Takeishi A, et al. (2024) Genetic engineering employing MPB70 and its promoter enables efficient secretion and expression of foreign antigen in bacillus Calmette Gu??rin (BCG) Tokyo. Microbiology and immunology.

Unali G, et al. (2023) Interferon-inducible phospholipids govern IFITM3-dependent endosomal antiviral immunity. The EMBO journal, 42(10), e112234.

Onnis A, et al. (2023) SARS-CoV-2 Spike protein suppresses CTL-mediated killing by inhibiting immune synapse assembly. The Journal of experimental medicine, 220(2).

Renzi F, et al. (2023) Engineering an ACE2-Derived Fragment as a Decoy for Novel SARS-CoV-2 Virus. ACS pharmacology & translational science, 6(6), 857.

Gunaratne GS, et al. (2023) Convergent activation of two-pore channels mediated by the NAADP-binding proteins JPT2 and LSM12. Science signaling, 16(799), eadg0485.

Cui Q, et al. (2023) The Apolipoprotein E neutralizing antibody inhibits SARS-CoV-2 infection by blocking cellular entry of lipoviral particles. MedComm, 4(5), e400.

Miluzio A, et al. (2023) Mapping of functional SARS-CoV-2 receptors in human lungs establishes differences in variant binding and SLC1A5 as a viral entry modulator of hACE2. EBioMedicine, 87, 104390.

Alcantara MC, et al. (2023) Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants. Vaccines, 11(3).